Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Dec 10 | 2019Sanofi To Move Away From Diabetes/CV; Sanofi 2019 Capital Markets DayPurchase Blast
$599
Posted in: Glucagon, Glucose Monitoring, Insulin Delivery Dec 10 | 2019Beta Bionics's iLet Breakthrough Designation; Roche Receives CE Mark for Novel BG Test; Glooko Receives ISO 13485 CertificationPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA Dec 09 | 2019High-Dose Trulicity Filed in EU (CHMP Agenda December 9-12)Purchase Blast
$599
Posted in: Bolus Insulin Dec 05 | 2019Arecor uRAI (AT247) Positive Topline ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Dec 04 | 2019Tirzepatide Ph3 Obesity Program Initiated (SURMOUNT-1)Purchase Blast
$599
Posted in: Basal Insulin Dec 04 | 2019Positive Lannett Bs-Glargine Ph1 Results; Zealand Initiates 2nd Ph3 CHI StudyPurchase Blast
$599
Posted in: Glucose Monitoring Dec 04 | 2019Dario BGM System Distributed on Walmart.com; Shares Climb ~50%Purchase Blast
$599
Posted in: Glucose Monitoring, Other Dec 02 | 2019Senseonics Launches Non-Adjunctive Claim; Dexcom Data Transmission Issue; Onduo RWE PublishedPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Nov 27 | 2019Thoughts on FDA Bs-Insulin Draft Guidance; Did Development Just Get Easier?Purchase Blast
$599
Posted in: Other Nov 26 | 2019Poxel Reports Positive Imeglimin Ph3 Japan Topline ResultsPurchase Blast$599
Posted in: Glucose Monitoring Nov 25 | 2019Dario Expands Retail Presence For Connected BGMPurchase Blast
$599
Posted in: Glucose Monitoring Nov 22 | 2019Lifescan Wins Patent Dispute vs. Pharma Tech SolutionsPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Other Nov 22 | 2019Sanofi Head of Strategy to Leave End of NovemberPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon Nov 20 | 2019Lilly to Invest $400M in Diabetes ManufacturingPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery, SGLT2i Nov 20 | 2019Novo 2019 Capital Markets Day Highlights and AnalysisPurchase Blast
$599
Posted in: SGLT2i Nov 20 | 2019Lexicon @ Stifel; First Presentation Since Empa T1DM AdcomPurchase Blast